Cingulate (CINGW) Total Current Liabilities (2021 - 2026)
Cingulate's (CINGW) quarterly Total Current Liabilities came in at $8.6 million in Q2 2026, down 16.31% quarter-over-quarter from $10.3 million in Q4 2025.
Analysis
Cingulate (CINGW) Total Current Liabilities (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Total Current Liabilities for 6 consecutive years, with $8.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Current Liabilities changed N/A year-over-year to $8.6 million; the trailing twelve-month figure through Jun 2026 stood at $8.6 million (changed N/A YoY), and the FY2025 full-year result was $10.3 million, up 107.41% from the prior year.
- Total Current Liabilities declined to $8.6 million in Q2 2026 per CINGW's latest filing, from $10.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $11.0 million in Q2 2023 and bottomed at $923505.0 in Q2 2022.
- Historically, Total Current Liabilities has averaged $5.7 million across 5 years, with a median of $5.8 million in 2023.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 1090.56% in 2023, then slumped 81.42% in 2024.
- Over 5 years, Total Current Liabilities stood at $7.0 million in 2022, then jumped by 45.82% to $10.2 million in 2023, then tumbled by 51.38% to $5.0 million in 2024, then jumped by 107.41% to $10.3 million in 2025, then dropped by 16.31% to $8.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $8.6 million, $10.3 million, and $5.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 32.65 Bn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | 37.11 Bn |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | 354.06 Mn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 1.31 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 8.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.63 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 5.88 Mn |
| Mar 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 4.97 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 2.25 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 5.73 Mn |
| Jun 30, 2023 | 10.99 Mn |
| Mar 31, 2023 | 6.66 Mn |
| Dec 31, 2022 | 7.01 Mn |
| Sep 30, 2022 | 6.41 Mn |
| Jun 30, 2022 | 923,505.00 |
| Mar 31, 2022 | 1.63 Mn |
| Dec 31, 2021 | 1.18 Mn |